Teva Pharmaceutical Industries Limited NYQ · TEVA

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

The Motley Fool · 9d ago

Teva Releases Q2 2026 Aide Memoire

GlobeNewswire Inc. · 30d ago

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

GlobeNewswire Inc. · 30d ago

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

The Motley Fool · 34d ago

Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?

The Motley Fool · 36d ago

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Benzinga · 38d ago

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

GlobeNewswire Inc. · 40d ago

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

GlobeNewswire Inc. · 40d ago

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

GlobeNewswire Inc. · 61d ago

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Benzinga · 80d ago

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy

Benzinga · 80d ago

Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - Kaken Pharma, Novartis, Glenmark Pharma, Sun Pharma, Teva Pharmaceutical, Bayer, and Galderma

GlobeNewswire Inc. · 86d ago

Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting

GlobeNewswire Inc. · 92d ago

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

GlobeNewswire Inc. · 94d ago

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

GlobeNewswire Inc. · 95d ago

Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032

GlobeNewswire Inc. · 99d ago

Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight

Investing.com · 107d ago

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

GlobeNewswire Inc. · 110d ago

BIO-Europe Spring® 2026: Partnering Momentum Builds as Global Biopharma Leaders Set Course for Lisbon

GlobeNewswire Inc. · 124d ago

Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding

The Motley Fool · 136d ago

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

GlobeNewswire Inc. · 137d ago

Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole

The Motley Fool · 141d ago

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

Benzinga · 145d ago

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

GlobeNewswire Inc. · 148d ago

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Benzinga · 151d ago